# Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients

> **NCT03792763** · PHASE2 · COMPLETED · sponsor: **Arbeitsgemeinschaft medikamentoese Tumortherapie** · enrollment: 8 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
- **DRUG:** Placebo 1.7 ml Subcutaneous Solution

## Key facts

- **NCT ID:** NCT03792763
- **Lead sponsor:** Arbeitsgemeinschaft medikamentoese Tumortherapie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-30
- **Primary completion:** 2023-09-14
- **Final completion:** 2023-09-14
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-02-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03792763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03792763, "Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03792763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*